HOSPIRA BORTEZOMIB 3.5 mg powder for injection vial

البلد: أستراليا

اللغة: الإنجليزية

المصدر: Department of Health (Therapeutic Goods Administration)

العنصر النشط:

bortezomib, Quantity: 3.5 mg

متاح من:

Pfizer Australia Pty Ltd

الشكل الصيدلاني:

Injection, powder for

تركيب:

Excipient Ingredients: mannitol; nitrogen

طريقة التعاطي:

Intravenous, Subcutaneous

الوحدات في الحزمة:

1 vial/pack

نوع الوصفة الطبية :

(S4) Prescription Only Medicine

الخصائص العلاجية:

Hospira Bortezomib Powder for Injection, in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy. Hospira Bortezomib Powder for Injection, as part of combination therapy, is indicated for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma. Hospira Bortezomib Powder for Injection is also indicated for the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease. Hospira Bortezomib Powder for Injection in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma.

ملخص المنتج:

Visual Identification: White, to off white lyophilized powder; Container Type: Vial; Container Material: Glass Type I Clear; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

الوضع إذن:

Licence status A

تاريخ الترخيص:

2017-11-03